PROTEINS, GENES AND THEIR USE FOR DIAGNOSIS AND TREATMENT OF BREAST CANCER

• Main Author: HERATH, HERATH, MUDIYANSELAGE, ATHULA, CHANDRASIRI
• Format: Patent
• Language: English; French
• Published: 22.02.2001
• Edition: 7
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; COMPOSITIONS THEREOF; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PHYSICS; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROCESSES OF PREPARING SUCH COMPOSITIONS; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; TESTING; VINEGAR; WINE

The present invention provides methods and compositions for screening, diagnosis and prognosis of breast cancer, for monitoring the effectiveness of breast cancer treatment, and for drug development. Breast Cancer-Associated Features (BFs), detectable by two-dimensional electrophoresis of serum are described. The invention further provides Breast Cancer-Associated Protein Isoforms (BPIs) detectable in cerebrospinal fluid, serum or plasma, preparations comprising isolated BPIs, antibodies immunospecific for BPIs, and kits comprising the aforesaid. L'invention concerne des procédés et des compositions servant au criblage, au diagnostic et aux prévisions en matière de cancer du sein, qui sont destinés au monitorage de l'efficacité d'un traitement du cancer du sein et au développement de nouveaux médicaments. On décrit des paramètres associés au cancer du sein et détectables par l'électrophorèse bidimensionnelle du sérum. En outre, l'invention concerne des isoformes de protéines associées au cancer du sein (IPCS) détectables dans le liquide céphalo-rachidien, le sérum ou le plasma, des préparations comprenant des IPCS isolées, des anticorps immunospécifiques aux IPCS et des dosages comprenant ceux-ci.